Protein C News and Research

RSS

Omicron variant of SARS-CoV-2 leads to less severe disease in mouse models

Georgia State University researchers have found that the Alpha, Beta and Delta variants of SARS-CoV-2 were substantially more fatal in mouse models than the original strain of the virus that causes COVID-19.

27 Jun 2022

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered due to toxicity or non-desirable effects.

27 Jun 2022

APOEε4 may confer increased risk for CTE-related neuropathological outcomes among older adults with repetitive head impacts

How could two individuals who both played football for 10 years and developed CTE have different disease severity? How could some individuals develop dementia in their 50's while other never develop dementia at all? Perhaps the answer lies in their genes.

27 Jun 2022

Lipid-peptide nanocomplexes offer new mRNA platform

A new paper reports the methodical development of lipid-peptide nanocomplexes as a delivery vehicle for messenger ribonucleic acid molecules to the tumor cell, in vitro and in vivo.

27 Jun 2022

Scientists create new fluorophores that could help fight cancer

Scientists from the Ural Federal University and the Ural Branch of the Russian Academy of Sciences have created new fluorescent chemical compounds (fluorophores) for photodynamic therapy of cancerous tumors, the latest method of treating cancer.

27 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Researchers evaluated the neutralizing ability of sera from COVID-19 patients.

27 Jun 2022

Chemically modified rocaglates have a stronger effect against viral replication

Hepatitis E virus (HEV) is widespread, and so far there is no effective drug. In the search for one, the so-called rocaglates have come into focus: plant compounds that can inhibit the replication of viruses.

27 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

A full model of the SARS-CoV-2 spike protein for studying its atomic-level dynamics by multiple microsecond simulations

Researchers constructed a full-length SARS-CoV-2 spike structure in its membrane-bound state to study functionally relevant aspects of its global conformational dynamics.

27 Jun 2022

Study investigates the virological attributes of Omicron in a Syrian hamster model

Researchers investigated the virological attributes of SARS‐CoV‐2 new variant of concern Omicron in a Syrian hamster model.

27 Jun 2022

Comparison of genome sequences of SARS-CoV-2 and other coronaviruses

Researchers compared the genomic sequence of SARS-CoV-2 and that of different coronaviruses.

27 Jun 2022

Does fecal viral excretion provide insights into on GI symptoms of COVID-19?

Researchers discuss the physiopathological mechanisms associated with digestive symptoms associated with COVID-19.

27 Jun 2022

C-reactive protein levels predict ED risk

A recent meta-analysis aimed to describe the relationship between C-reactive protein levels and erectile dysfunction.

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Protein C News and Research

Omicron variant of SARS-CoV-2 leads to less severe disease in mouse models

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

APOEε4 may confer increased risk for CTE-related neuropathological outcomes among older adults with repetitive head impacts

Lipid-peptide nanocomplexes offer new mRNA platform

Scientists create new fluorophores that could help fight cancer

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Chemically modified rocaglates have a stronger effect against viral replication

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

A full model of the SARS-CoV-2 spike protein for studying its atomic-level dynamics by multiple microsecond simulations

Study investigates the virological attributes of Omicron in a Syrian hamster model

Comparison of genome sequences of SARS-CoV-2 and other coronaviruses

Does fecal viral excretion provide insights into on GI symptoms of COVID-19?

C-reactive protein levels predict ED risk

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Mice study unravels the role of T. denticola in Alzheimer's disease pathogenesis

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Inhibiting pore formation in cells may facilitate prevention, treatment of NASH-associated liver cancer

Study uncovers cryptic vulnerabilities in RET oncogene that could aid in anti-cancer drug design

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News